Helix to develop insulin skin patch for diabetics :
This article was originally published in Clinica
Canada's Helix BioPharma is hoping to develop an insulin-delivering skin patch following success with the product in preclinical trials. Animal studies have shown that its Biphasix skin patch was able to deliver insulin in sustained quantities. Blood glucose levels were significantly reduced and remained reduced for more than 30 hours in diabetic rats treated with porcine insulin using the patch, said Helix of Aurora, Ontario. The company plans to develop human insulin formulations on a patch to reduce the need for injections.
You may also be interested in...
The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.
Through its partnership with majority stakeholder Nanjing King-Friend Biochemical Pharmaceutical, Meitheal Pharmaceuticals has received FDA approval for enoxaparin, a generic rival to Lovenox.
The European Commission has granted a marketing authorization for UCB and Amgen’s bone-building MAb, romosozumab, and first launches are expected in the first half of 2020; patient groups suggest that the prevention and treatment of fragility fractures has not attracted the attention it deserves.